Abionyx Pharma, a biotech company dedicated to the discovery and development of therapies based on natural recombinant ApoA-I, has successfully completed a second batch for the GMP industrial biomanufacturing of CER-001 using an innovative and robust method. This confirms that Abionyx’s new production line is ready to enter the Apotherapy market, based on the only natural recombinant ApoA-I protein. All stages of the biomanufacturing process are designed to increase production yields, enablin...